

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet	1	of	1
-------	---	----	---

**Complete If Known**

Application Number	10/568133
Filing Date	May 9, 2006
First Named Inventor	Michael Didriksen
Art Unit	1617
Examiner Name	Ramachandran, U.
Attorney Docket Number	447-US-PCT

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Footnote
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
W ↓		WO 97/20553 A1	06-12-1997	Javitt, D.		
		WO 97/45115 A1	12-04-1997	Trophix Pharm. Inc.		
		WO 02/08216 A1	01-31-2002	H. Lundbeck A/S		
		WO 03/053942 A1	07-03-2003	H. Lundbeck A/S		

Examiner Signature	<i>Christine</i>	Date Considered	<i>6/29/10</i>
-----------------------	------------------	--------------------	----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

***If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.***

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/568,133
				Filing Date	February 10, 2006
				First Named Inventor	Michael Didriksen
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	05432/100N212-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>4</sup> -Number-Kind Code <sup>5</sup> (if known)				
	BA	EP 0687 472 A2	12-20-1995	Eli Lilly and Company		
	BB	EP0 714 663 A2	06-05-1996	Eli Lilly and Company		
	BC	WO 97/28141	08-07-1997	Pierre Fabre Medicament		
	BD	WO 96/03400	02-08-1996	PFIZER INC.		
	BE	EP-A-701819	08-16-2000	PFIZER INC.		
	BF	WO 99/13877	03-25-1999	ASTRA AKTIEBOLAG		



\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	CA	Trends in Pharmacological Sciences, - 5HT <sub>1A</sub> receptor antagonists in combination therapy - 5-HT and antidepressants: new views from microdialysis studies- TIPS - July 1993 (Vol. 14) - 2 pages.		
	CB	Pierre Blier, M.D. et al. - Journal of Clinical Psychopharmacology; Copyright 1987; Modifications of the Serotonin System by Antidepressant Treatments: Implications for the Therapeutic Response in Major Depression - pages 24S-35S.		
	CC	Roberto Invernizzi et al. - Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex - Brain Search, 584 (1992); pages 322-324.		
	CD	Stephan Hjorth - Serotonin 5 HT <sub>1A</sub> Autoreceptor Blockade Potentiates the Ability of the 5-HT Reuptake Inhibitor Citalopram to Increase Nerve Terminal Output of 5-HT In Vivo: A Microdialysis Study; Journal of Neurochemistry; 1993 International Society of Neurochemistry.		
	CE	Robert B. Innis et al.; Pertussis toxin blocks 5-HT <sub>1A</sub> and GABA <sub>B</sub> receptor-mediated inhibition of serotonergic neurons; European Journal of Pharmacology, 143 (1987); pages 195-204.		
	CF	S.E. Gartside et al.; Interaction between a selective 5HT <sub>1A</sub> receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT; British Journal of Pharmacology (1995) 115, 1064-1070.		
	CG	Pierre Blier et al. - Current advances and trends in the treatment of depression - 1994, Elsevier Science Ltd.; TIPS - July 1994 (Vol. 15), pages 220-226.		
	CH	Wojciech Danyasz et al. Glycine and N-Methyl-D-Aspartate Receptors: Physiological Significance and Possible Therapeutic Applications; Pharmacological Reviews; Copyright 1998 by The American Society for Pharmacology and Experimental Therapeutics; Vol. 50 No.		

Examiner Signature	<i>Wojciech Danyasz</i>	Date Considered	6/29/07
-----------------------	-------------------------	--------------------	---------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete If Known</b>	
				Application Number	10/568,133
				Filing Date	February 10, 2006
				First Named Inventor	Michael Didriksen
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	05432/100N212-US1

		4; pages 598-664.	
	CI	Gabriel Nowak et al. - Strychnine-insensitive Glycine/NMDA Sites Are Altered In Two Stress Models of Depression; Polish Journal Of Pharmacology Pl. J. Pharmacol, 1998, 50, pages 365-369.	
	CJ	Mariusz Papp et al.- Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression; European Journal of Pharmacology 315 (1996) 145-151.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	6/29/02
-----------------------	---	--------------------	---------